Clinical Trials Directory

Trials / Unknown

UnknownNCT04660630

A Real World Research: Comparison of Precision and Experience Therapy for Hypertension, Diabetes or Hyperlipidemias

Real World Research Based on Genomics: Comparison of Precision and Experience Therapy for Chronic Cardiovascular and Cerebrovascular Diseases

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
1,172 (actual)
Sponsor
Beijing Chao Yang Hospital · Academic / Other
Sex
All
Age
55 Years – 120 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the effectiveness, safety and health economics of precise drug use strategies based on pharmacogenomics compared with traditional drug use strategies for cardiovascular related chronic diseases.

Detailed description

This study is a randomized controlled, single blind, multicenter clinical study. Beijing Chaoyang Hospital is the team leader, and director Liu Lihong is the project leader. The sub center is Daming County Street Town Health Center and Daming County Jiuzhi township health center. The team leader is responsible for the formulation, implementation and coordination of the research plan, and each sub center is responsible for the implementation of the specific study, patient management and research information feedback. Three project groups were set up in this study: primary hypertension, type 2 diabetes and hyperlipidemia. In each group, the control group and the experimental group were set up, and the patients in two pilot towns of Daming County were selected by cluster stratified random sampling. The control group received the treatment of local researchers according to the traditional medication strategy. The patients in the experimental group were treated with the drug regimen formulated by local researchers according to the results of their pharmacogenomic test reports. The subjects were single blind.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTGene detection of therapeutic drugs for chronic cardiovascular and cerebrovascular diseasesAccording to the results of drug gene chip detection, we combined with the clinical characteristics of the patient to choose more suitable cardiovascular and cerebrovascular treatment drugs.
BEHAVIORALRegular follow-up and patient educationThe subjects received regular follow-up and patient education.

Timeline

Start date
2020-01-21
Primary completion
2023-12-20
Completion
2025-01-20
First posted
2020-12-09
Last updated
2020-12-09

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT04660630. Inclusion in this directory is not an endorsement.